AstraZeneca: chronic kidney disease trial stopped early
(CercleFinance.com) - A Phase III trial of AstraZeneca's drug Farxiga has been stopped early after independent monitors determined that the drug was shown to be effective against chronic kidney disease, the drugmaker said on Monday.
The study will be stopped following a recommendation from an independent Data Monitoring Committee (DMC) based on the determination of "overwhelming efficacy," it said.
AstraZeneca also said on Monday that its Imfinzi drug has been approved in the US as a first-line treatment for adult patients with extensive-stage small cell lung cancer, a highly aggressive form of lung cancer that typically recurs and progresses rapidly despite chemotherapy.
The AstraZeneca share is currently up 0.4% on the London Stock Exchange.
Copyright (c) 2020 CercleFinance.com. All rights reserved.